CVS Health Corp said on Wednesday it would administer Eli Lilly & Co's experimental antibody treatment to COVID-19 patients in their homes and in long-term care facilities through a U.S.
This data is encouraging as it reinforces the large and growing body of evidence indicating that certepetide can enhance the targeting, penetration, and effectiveness of therapeutic agents - in this ...
| According to DataM Intelligence AUSTIN, Texas and TOKYO, Oct. 27, 2025 /PRNewswire/ -- The Antibody-Drug Conjugates (ADC) Market Size was valued at around US $11.9 billion in 2024, the market is ...
Protinah, a new drug development company specializing in protein-protein interaction (PPI) big data, announced on November 5 that it has been selected ...
The brain drug developer plans to slash R&D expenses by about 60% in the wake of the FDA surprisingly rejecting its rare disease drug Vyglxia.
The deal hands Blackstone a piece of the potential future sales of an antibody-drug conjugate that could soon challenge marketed medicines from AstraZeneca and Gilead.
Health Canada has conditionally approved the drug lecanemab to slow early-stage Alzheimer's disease, raising questions about ...
Syngene International announces plans to add bioconjugation suite for end-to-end Antibody-Drug Conjugates Development Bioconjugation capability will complement commercial payload, linker and ...
Asianet Newsable on MSN
Merck Stock Rises Upon Receipt Of $700M In Funding For Experimental Cancer Drug
Shares of Merck (MRK) traded 1% higher on Tuesday afternoon after the company said that it has entered into a funding ...
GlycoNex, Inc. (4168, hereinafter referred to as GNX), today announced that the last patient has received the final dose in ...
US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) has entered a license and collaboration deal with OPKO Health’s (Nasdaq: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback